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Positron emission tomography (PET) and radiolabeled 3,4-Dihydroxy-phenyl-L-alanine (L-DOPA) have been used to study presynaptic dopaminergic function in vivo for several years. L-DOPA has been radiolabeled with different positron-emitting nuclides, II C-labeled L-DOPA in �-position, L-[�_ II C]DOPA, and ls F-labeling in 6 po sition on the aromatic ring giving the analogue L-6-e S F]fluorodopa ( Fig. 1) , are commonly used today. These tracers have both been shown to reveal the pre synaptic dopaminergic function in healthy and patho logic states of humans (Garnett et aI., 1983; aI., 1991; Leenders et aI., 1986; Tedroff et aI., 1992a) . However, divergent estimates of the specific striatal utilization have been indicated using L- [�_ 11 C] DOPA and L-6-[ ls F]fluorodopa, e.g., regarding a possible in creased dopamine synthesis rate in schizophrenia as compared to healthy volunteers (Dao-Castellana et aI., 1997; Hietala et aI., 1995; Lindstrom et aI., 1998; Reith et aI., 1994) .
Some earlier comparisons of the two tracers imply a similar distribution and metabolism (Fimau et aI., 1986; Firnau et aI., 1987) . Other studies indicate differences with respect to the affinity for the metabolic enzymes, especially the peripheral formation rate of the major me tabolite the corresponding 3-0-methy1dopa and the blood-brain clearance of the tracers (Cumming et aI., 1995; Cumming et aI., 1987; Melega et aI., 1990) .
The comparisons compose not only possible differ ences due to the effects of introduction of fluorine into the aromatic ring but methodologic differences as well. The use of different radionuclides, such as 3H compared to 14e, may yield large differences in specific radioac tivity, and tritium exchange during the radioanalysis pro cedure could influence the outcome of the measure ments. To evaluate differences and similarities of the L-DOPA and its 6-fluoroanalogue as tracers for the pre synaptic dopaminergic system PET experiments were performed in anesthetized monkeys with both molecules labeled with lIe in l3-position. Effects induced by phar macologic challenges were studied with respect to the radiotracer influx rate constant, Kj, in striatum and ra dioactivity disposition in plasma. Additional experiments were also performed with site-specific li e-labeling in carboxylic position, and the effect on the calculated Kj value was studied.
MATERIALS AND METHODS

Animals and drugs
Female rhesus monkeys (Macaca mulatta) 20 to 30 years of age weighing 5 to 11 kg from the Primate Research Laboratory ofUppsala University PET Centre were used after an overnight fast. The monkeys were housed in groups of four to eight animals for at least 4 months before the study. The studies were approved by the Animal Ethics Committee of Uppsala Univer sity (permission C03/92, C289/94, and C338/97). Anesthesia was induced with 100 mg intramuscular ketamine (Ketalar, Parke Davis, Morris Plains, NJ, U.S.A.). After transport of the anesthetized monkey to the investigation area of the Uppsala University PET Centre, a venous catheter was inserted into each hind leg of the monkey, one for administration of anes thetic drugs and blood sampling, and the other for administra tion of the radioactive tracer.
Tracheal intubation was followed by muscle relaxation with 5 mg/kg/h intravenous atracurium (Tracrium, Wellcome, Lon don) and mechanical ventilation with 30% oxygen in air. An esthesia was maintained with a dose of 8 to 12 mg/kg/h intra venous propofol (Diprivan, ICI). Vital signs including blood pressure, heart and respiratory rate, and body temperature were monitored throughout the investigation. In all studies, recovery from 'anesthesia was unremarkable. 6, 7, 
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Radiochemical synthesis
The IIC radionuclide was produced by a 1 4 N (p,Cl') IIC re action using the MCI7 cyclotron (Scanditronix, Uppsala) at the Uppsala University PET Centre and obtained as e ICjcarbon dioxide. The synthesis of L- [[3-IICjDOPA (Bjurling et aI., 1990 ) and L-6-[!3_IICjt1uorodopa (Bjurling et aI., 1991b ) was performed using a combination of organic synthesis methods and a multi enzymatic procedure. The synthesis of the corre sponding carboxy-IIC-labeled tracer was performed in a simi lar manner (Bjurling et aI., 199Ia) . ring (Ostertag et aI., 1989) , and filtered with a 4.2-mm Hanning filter.
Realignment of PET scans and definition of region of interests
Summation images were constructed for each scan using data collected 20 to 60 minutes after tracer injection by the use of computer software supplied with the tomograph. A realign ment method was used when necessary (>0.5 mm head move ment) to prevent movements between scans from causing arti factual increases or decreases in the calculated Ki of the tracer (Anderson, 1995) . Briefly, the method is based on using a mask of one reference data set (e.g., baseline) made from voxels with high signal-to-noise ratio in comparison to a sample data set (e.g., perturbation). The result of the comparison is a matrix against which both data sets are resliced. After this procedure, an average image was formed using the summation images 
Calculations of PET data
Time-activity curves were generated and used to reconstruct images according to the mathematical background as described
previously (Patlak 
Plasma sample preparation and high-performance liquid chromatographic analysis
Venous blood samples were collected at 5, 25, 45, and 50 minutes after tracer injection, and centrifuged at 4000 rpm for 2 minutes. Proteins were precipitated with 45 [LI of 5 molfL perchloric acid in 0.8 mL of plasma. After centrifugation for 3 minutes at 15,000 rpm, the supernatant was filtered through an acetate filter (0.22 [Lm, Dynagard®, Microgon Inc, U.S.A.) yielding =0.5 mL of sample. High performance liquid chroma tography analysis of the composition of the IIC-derived radio activity was performed as described previously with minor modifications (Lindner et aI., 1995) . Before injection into the chromatographic system a ·15 [LL standard solution yielding 0.1-0.2 mmolfL of reference compounds was added to the sample. Separation of llC-labeled tracer and derived labeled metabolites was performed on a C-18 column (U ltracarb ODS20, 3 [Lm 100x4.6 mm i.d., Phenomex, Scanditec). The composition of the mobile phase was 0.1 molfL acetate-citrate, I mmolfL edetic acid, 5 mmolfL sodium heptanesulphonate, and 12.5% methanol. The pH was 3.7 in the final buffer. The recovery of radioactivity from plasma after protein precipitation was 82 ± 7% and in the chromatographic step 101 ± 8%, n = 26. 
Statistical analysis
The paired t-test was used to evaluate induced changes from pharmacologic challenge in comparison to baseline conditions. The calculated Kj value was lower for both tracers when labeled in the carboxylic position, Table 3 . The Kj value of carboxy-labeled tracer decreased as compared to !3-labeling with 77% on average for the fluorinated ana- Sequential scans were performed in each monkey (n = 13) with both tracer on the same day. *p < 0.05; paired t-test.
log and 101% with the L-DOPA tracer. A significant Kj-value was still present on carboxy-labeling of the flu orinated analog (regression analysis; P < .05; Table 3 ). Typical Patlak curves used for the calculation of striatal Kj values of the 13-and carboxy-labeled tracers are shown in Fig. 2 .
11 C]DOPA and L-6-[p_ ll C]fluorodopa striatal Kj 6R-BH4 (5 mg/kg/h) increased the striatal L-[I3-ll C]DOPA Kj with a mean value of 13 ± 13% (P < .05; Table 4 ; Fig. 3 ). In otherwise identical conditions, the striatal Kj value measured for L-6-[I3-II C]fluorodopa was not significantly different than the baseline value ob served in the �ame monkey -1 ± 16% (Table 4 ; Fig. 3) Effects of tolcapone on the striatal K; before and after 6R-BH4 infusion Tolcapone (10 mg/kg/h) increased the striatal Kj of L-6-[I3-II C]fluorodopa with an average of 32 ± 6% (P < .01; from baseline; Table 4 ; Fig. 3 ). The Kj values were also significantly increased from baseline value after challenge with both 6R-BH4 and tolcapone (45%; P < .01; Table 4 ; Fig. 3) . Compared with the tolcapone chal lenge alone, a significant increase of the striatal L-6-[13-l1 C]fluorodopa Kj was observed in monkeys after challenge with both 6R-BH4 and tolcapone (13%; P < .05; one-way analysis of variance; Table 4 ; Fig. 3) .
In a previous study with identical experimental con ditions as in the present study, tolcapone treatment did not change the measured striatal Kj compared to baseline values with L-[I3-lI C]DOPA in monkeys (Hartvig et aI., 1992) . These result are included in Table 4 . Compared with the 6R-BH4 challenge alone, no further effects on the striatal L-[I3-II C]DOPA Kj were induced by the chal lenge with both tolcapone and 6R-BH4 (P = .31; Table  4 ; Fig. 3 ).
Measurement of radioactive metabolites in plasma samples
A difference between metabolite formation rates of the two tracers L-[I3-II C]DOPA and L-6-[13-1I C]fluorodopa was measured on plasma analysis of tracer and radioac tive metabolites (Fig. 4A) . At baseline conditions, 60 ± II d' d' 4% of unchanged L-[±-C]DOPA was etermme m plasma 50 minutes after tracer injection, and the 3-0-methylated fraction accounted for 25 ± 4% of the total radioactivity. The relation was inverse for L-6-[I3-lI C]fluorodopa; 30 ± 3% of unchanged tracer and 57 ± 7% of 3-0-methyl metabolite was present at 50 minutes.
6R-BH4 did not induce any discernible effect on the rate of metabolism in plasma of any of the tracers studied (data not shown). Tolcapone changed the relative radio active fraction of the tracer and its metabolites in plasma as expected and the 3-0-methyl metabolite fraction was reduced to between 0 to 5% of total radioactivity (Fig.  4B) . The homovanillic acid fraction also decreased to zero values whereas the 3,4-dihydroxy-phenylacetic acid fraction increased.
DISCUSSION
6R-BH4, a cofactor for tyrosine hydroxylase, was used as a tool to enhance the dopamine synthesis rate. The constant rate infusion of 6R-BH4 (5 mg/kg) induced a significant increase of the striatal L-[13-11 C]DOPA Kj that 
L-UV'ClOOPA 0.0135 ± 0.002 0.0154* ± 0.001 13 ± 13 O± 2+ 0.0151*±0.001 11 ± 6 n = 8 n = 6 n = 4 L = 6 = f[3-IICltluorodopa 0.0132 ± 0.002 0.0125 ± 0.003 -1±16 0.0178* ± 0.002 32 ± 6 0.0189t ± 0.002 45 ± 12 n = 10 n = 8 n = 4 n = 6 n = number of monkeys and "change" indicates the mean value of each individual change from its own baseline value.
* p < 0.05; paired t-test from baseline in same monkey. t p < 0.05; from to1capone treatment. one-way ANOV A with repeated measure.
+ Taken from Hartvig et a!.. (1992).
was in accordance with earlier studies showing the modulating properties of 6R-BH4 on the dopamine syn thesis rate in rats (Tsukada et a!., 1994) and in monkeys Tsukada et a!., 1996) . The proposed mechanism of action is that 6R-BH4 induces a higher formation rate of endogenous L-DOPA, which in turn regulates the AADC activity (Misu et a!., 1996 et aI., 1997). The 6R-BH4-induced increase in aromatic L-amino acid decarboxylase (AADC) activity and has been verified in an AADC activity assay in rats in which the conversion of L-DOPA to dopamine is measured (Torstenson et aI., in manuscript) . The dopamine releasing effect induced by 6R-BH4 (Koshimura et aI., 1990) could theoretically decrease the apparent influx rate constant due to a release of the trapped radioactivity in the striatum. This influence on the calculated value is less likely because PET studies with a potent dopamine releasing agent, e.g., amphet amine, did not decrease the measured striatal Kj for L-[(3-II C]DOP A (Hartvig et aI., 1997) . In contrast to the increase striatal Kj value measured with L-[(3_ II C]DOPA, 6R-BH4 induced no significant change of the measured striatal Kj value compared to the baseline with L-6-[(3-I' C]fluorodopa.
IS F-Iabeled L-6-fluorodopa has been evaluated with a variety of models using different methods to calculate the utilization rate of the tracer in vivo with PET. This includes methods using metabolite corrected arterial plasma input function also regarding the 3-0-methyl fraction competition for the transport enzyme (Gjedde et aI., 1991; Kuwabara et aI., 1993; Kuwabara et aI., 1995) , as well as the tissue reference ratio model (Patlak and Blasberg, 19�5; Cumming and Gjedde, 1998) .
Estimation of the striatal Kj for L-[(3_ II C]DOPA with
PET has been performed with a reduced three-compart ment model (Hartvig et aI., 1991; Patlak and Blasberg, 1985; Tedroff et aI., 1992b ) using a reference region in the brain with negligible AADC activity. This model might be sensitive to radio labeled metabolites formed in the periphery that pass the blood-brain barrier and inter fere unequally with the reference and the target region (Sawle et aI., 1994) . L-6-[ '8 F] fluorodopa has been shown in vitro to have a low affinity for the catechol-O-methyl transferase (COMT) enzyme (Creveling and Kirk, 1985) , and this was one of the reasons for choosing 6 position labeling instead of, e.g., 2 position (Cumming et aI., 1988) . Stud ies of radiolabeled tracer and metabolites in plasma have indicated that native L-DOPA has higher affinity than the fluoroanalogue for the COMT enzyme (Firnau et aI., 1987; Firnau et aI., 1988) . The present study showed an extensive 3-0-methyl metabolite formation of the fluo roanalogue, which the L-[(3_ II C]DOPA tracer did not ex hibit. This higher rate of 3-0-methyl-6-fluorodopa for mation corresponds well with studies on IS F-Iabeled F DOPA and 3 H-Iabeled DOPA in rats (Cumming et aI., 1995) .
The 3-0-methyl metabolite enters the brain in substan tial amounts (Doudet et aI., 1991; Reith et aI., 1990 ) and hence will interfere in the calculation of the striatal Kj value using a brain reference area (Sawle et aI., 1994) . A significant contribution of radioactivity from this metabolite in the brain would decrease the calculated spe cific use in the target tissue due to an increased back ground radioactivity in the tissue-reference model as pre dicted in the original method description by Patlak and Blasberg (1985) . This influence of different peripheral metabolite formation rates is also found in the baseline striatal Kj value of the two tracers where the L-[(3-II C]DOP A tracer showed a 11 % higher value as com pared to L-6-[(3-1 I C]fluorodopa. Previously, a 48% base line difference between the two tracers was reported (Hartvig et aI., 1992) . However, the monkeys in that study received either L-[I3_ 1I C]DOPA or L-6-[I3-II C]fluorodopa so the interindividual variation of about 20% shown for both tracers in baseline striatal Kj value (Table 2 ) might explain these divergent estimates.
The 3-0-methyl metabolite fraction was reduced to less than 5 % of total plasma radioactivity, and the striatal Kj value of the I I C-labeled fluoroanalogue was increased with 32% after COMT inhibition with tolcapone. This corresponds well with previ o us results in monkeys and humans with L-6-[ '8 F]fluorodopa and PET after COMT inhibition (Doudet et aI., 1997; Sawle et aI., 1994) . The striatal Kj values measured with lI C-labeled L-DOPA was shown not to be dependent on COMT inhibition in identical PET studies as in the present study (Hartvig et aI., 1992; Tedroff et aI., 1992b) . The COMT inhibition in the present study did not induce any additional change in the striatal L-[(3-1 I C]DOPA Kj which strengthens the ob servation. Pretreatment with COMT inhibition and 6R-BH4 in fusion increased the Kj value of the fluoroanalogue by 45% on average compared with 32% without COMT inhibition. This 6R-BH4 induced increase was in parallel with the increase (+13%) measured with L-[±_ II C]DOPA as tracer without COMT inhibition. Hence, only after COMT inhibition was it possible to detect the stimula tion of the Kj value of fluorodopa produced by 6R-BH4 using the present tissue-slope method.
II C-Iabeling of L-DOPA and L-fluorodopa in the car boxylic-position in the molecule (Fig. 1) would imply that the II C-label is lost as [ 11 C]C02 in the brain due to the activity of AADC, no radioactivity accumulates in the striate and the measured Kj value should approach a zero value. Site-specific I I C-labeling in carboxylic posi tion reduced the radioactivity accumulation for both trac ers. However, the reduction differed between the two tracers. The striatal Kj value measured with the L-[(3-II C]DOP A tracer approached zero whereas the flu oro analogue did not reach a zero-value (average 77% de crease). Radiolabeled tracer or formed metabolites ap peared to be specifically retained in the striatum when using the fluoroanalogue giving a measurable rate con stant. One hypothesis is that peripherally formed 3-0-methyl metabolite has affinity for the AADC enzyme without any conversion to 3-0-methylfluorodopamine R. TORSTENSON ET AL.
and hence is retained in the striatum. This hypothesis is strengthened by a visualization of the striatum after ad ministration of the radiolabeled 3-0-methyl fluoro metabolite (Wahl et aI., 1994) . Correction for the 3-0-methyl fraction influence in the calculation of the Ki value of the fluoroanalogue is cum bersome and is supported by the massive literature in the area (Cumming and Gjedde, 1998) . Large differences in hepatic COMT activity exist within species (also sex differences) (Cumming et aI., 1993; De Santi et aI., 1998) and also between species (Guldberg and Marsden, 1975) which implies difficulties in introducing standard corrections in the calculations of PET data. COMT in hibition in connection with the PET study would be the only way to avoid a possible 3-0-methyl metabolite in teraction in the brain with the AADC enzyme.
There may also be an affinity difference of the two radiotracers for the AADC enzyme in the brain. C]DOPA (Cumming et aI., 1988) . The L-6-[I3-ll C]fluorodopa Ki value increased by 32% after COMT inhibition and the baseline difference between the tracers was only 11 %. This might indicate that the fluoroana logue has a higher formation rate to fluorodopamine in vivo than th y endogenous molecule to dopamine. This is still a matter for further studies.
In conclusion, the two studied 13-1 1 C-Iabeled mol ecules L-DOPA and L-fluorodopa have different metabo lism and distribution. The extensive 3-0-methyl metabo lite formation of the fluoroanalogue seems to obscure the 6R-BH4 induced effect on dopamine synthesis rate as evaluated with PET. It seems feasible to compare quan titative data from clinical and research studies performed with the two tracers evaluated with tissue-slope method if COMT inhibition is performed for the fluoroanalogue. Careful interpretation of data, however, should be made when including a new pharmacologic challenge in a study that would give new influences not easily foreseen.
